

Article title: IMPACT OF BODY MASS INDEX ON THE EFFICACY OF BIOLOGICAL THERAPIES IN PATIENTS WITH PSORIASIS: A REAL-WORLD STUDY

Journal name: Clinical Drug Investigation

Author names: Federico Pirro, Giacomo Caldarola, Andrea Chiricozzi, Martina Burlando, Marco Mariani, Aurora Parodi, Ketty Peris, Clara De Simone

Corresponding author: Federico Pirro, Institute of Dermatology, Catholic University, Rome – Italy AND Department of Dermatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome – Italy (email: federico.pirro90@gmail.com)

Supplementary Table 1. Table representing, by drug, number (%) of: total patients, naive patients, biological experienced patients (and specific class of biological drug), the number of patients with loss of efficacy at 24 months.

Adalimumab (N=174)	N (%)
Naive	109 (62.64)
Previous Biological therapies	65 (37.36)
<i>Anti-TNF only</i>	56 (32.18)
<i>Anti-IL17 only</i>	0 (0.00)
<i>Ustekinumab only</i>	2 (1.15)
<i>Anti-TNF, anti-IL17</i>	0 (0.00)
<i>Anti-TNF, Ustekinumab</i>	3 (1.72)
<i>Anti-TNF, anti-IL17, Ustekinumab</i>	1 (0.59)
<i>Anti-IL17, Ustekinumab</i>	0 (0.00)
<i>Other/N.A.</i>	3 (1.72)
Loss of efficacy (month 24)	57 (32.76)
Etanercept (N=146)	
Naive	117 (80.14)
Previous Biological therapies	29 (24.79)
<i>Anti-TNF only</i>	22 (18.80)
<i>Anti-IL17 only</i>	0 (0.00)
<i>Ustekinumab only</i>	0 (0.00)
<i>Anti-TNF, anti-IL17</i>	0 (0.00)
<i>Anti-TNF, Ustekinumab</i>	2 (1.71)
<i>Anti-TNF, anti-IL17, Ustekinumab</i>	0 (0.00)
<i>Anti-IL17, Ustekinumab</i>	0 (0.00)
<i>Other/N.A.</i>	5 (4.28)
Loss of efficacy (month 24)	42 (28.77)
Ixekizumab (N=123)	
Naive	61 (49.59)

Previous Biological therapies	62 (50.41)
<i>Anti-TNF only</i>	27 (21.95)
<i>Anti-IL17 only</i>	1 (0.81)
<i>Ustekinumab only</i>	5 (4.07)
<i>Anti-TNF, anti-IL17</i>	1 (0.81)
<i>Anti-TNF, Ustekinumab</i>	14 (11.39)
<i>Anti-TNF, anti-IL17, Ustekinumab</i>	11 (8.94)
<i>Anti-IL17, Ustekinumab</i>	1 (0.81)
<i>Other/N.A.</i>	2 (1.63)
Loss of efficacy (month 24)	8 (6.50)
Secukinumab (N=122)	
Naive	48 (39.34)
Previous Biological therapies	74 (60.66)
<i>Anti-TNF only</i>	50 (40.98)
<i>Anti-IL17 only</i>	1 (0.82)
<i>Ustekinumab only</i>	3 (2.46)
<i>Anti-TNF, anti-IL17</i>	2 (1.64)
<i>Anti-TNF, Ustekinumab</i>	15 (12.30)
<i>Anti-TNF, anti-IL17, Ustekinumab</i>	3(2.46)
<i>Anti-IL17, Ustekinumab</i>	0 (0.00)
<i>Other/N.A.</i>	0 (0.00)
Loss of efficacy (month 24)	15 (12.30)
Ustekinumab (N=141)	
Naive	62 (43.97)
Previous Biological therapies	79 (56.03)
<i>Anti-TNF only</i>	65 (46.10)
<i>Anti-IL17 only</i>	0 (0.00)
<i>Ustekinumab only</i>	6 (4.25)
<i>Anti-TNF, anti-IL17</i>	1 (0.71)
<i>Anti-TNF, Ustekinumab</i>	4 (2.84)
<i>Anti-TNF, anti-IL17, Ustekinumab</i>	1 (0.71)
<i>Anti-IL17, Ustekinumab</i>	0 (0.00)
<i>Other/N.A.</i>	2 (1.42)
Loss of efficacy (month 24)	19 (13.48)